Breast Endocrine And Surgical Oncology

Written by internationally acclaimed specialists, Breast, Endocrine and Surgical Oncology provides pertinent and concise procedure descriptions spanning benign and malignant problems and minimally invasive procedures. Complications are reviewed when appropriate for the organ system and problem, creating a book that is both comprehensive and accessible. Stages of operative approaches with relevant technical considerations are outlined in an easily understandable manner. The text is illustrated throughout by photographs that depict anatomic or technical principles. Forming part of the series, Surgery: Complications, Risks and Consequences, this volume Breast, Endocrine and Surgical Oncology provides a valuable resource for all general surgeons and residents in training. Other healthcare providers will also find this a useful resource.

With an emphasis on the “hows and whys” of contemporary surgery, Operative Techniques in Breast, Endocrine, and Oncologic Surgery, Second Edition, features concise, bulleted text, full-color illustrations, and intraoperative photographs to clarify exactly what to look for and how to proceed. Drawn from the larger Operative Techniques in Surgery, Second Edition, this concise, stand-alone surgical atlas, overseen by editor-in-chief Mary T. Hawn and meticulously edited by Dr. Michael S. Sabel, focuses on the steps of each technique, rapidly directing you to the information you need to choose the right approach for each patient, perform it successfully, and achieve the best possible results.

This textbook provides a comprehensive overview of the state of the art knowledge of breast cancer management for the modern breast surgeon. It covers all aspects of multidisciplinary care including primary breast and axillary surgery, reconstruction and oncoplastic techniques, external beam radiotherapy and newer techniques such as tomotherapy, intraoperative radiotherapy and brachytherapy. In addition, systemic therapies including chemotherapy, the latest biological targeted therapies and endocrine therapies are covered. Readers can find out about other important aspects of breast cancer such as genetics, screening, imaging and long-term health among others. Chapters take the reader through the basics up to the highest levels of knowledge in an easy to understand format with management algorithms to aid clinical care, generous referencing of the best literature and figures and photographs to illustrate each section. Published with the official approval of the European Society of Surgical Oncology (ESSO) and the European Society of Breast Cancer Specialists (EUSOMA), the book is written by a panel of recognised leaders in the field and is an indispensable guide for the practicing breast specialist and senior specialists in training, wishing to update their knowledge with the latest trends or polish off their training before accreditation.

Endocrine Neoplasia is a comprehensive, updated, and clearly-written text covering the diseases for which endocrine surgical expertise is often needed. We look towards advances in the science and the art of endocrine surgery to continuously improve outcomes for our patients. The goal of this text was to provide a detailed description of both the underlying science of disease as well as the art of clinical management. The book is divided into five sections addressing neoplasms of the thyroid, parathyroid, adrenal gland, neuroendocrine pancreas, and multiple endocrine neoplasia. Experts from the United States, Canada, and Australia have contributed chapters addressing both the biology of endocrine tumors and the clinical management of disease. Recent discoveries regarding the genetic underpinnings of disease are highlighted. Updated consensus guidelines were used for clinical recommendations. The management of complex and often confusing clinical problems is discussed in detail.

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Kelly Hunt, is devoted to Changing Paradigms in Breast Cancer Diagnosis and Treatment. Dr. Hunt has assembled expert authors to review the following topics: Tomosynthesis in breast cancer imaging: how does it fit into preoperative evaluation and surveillance?; Lobular breast cancer: different disease, different algorithms?; Hypofractionated radiation therapy in breast conserving therapy; Oncoplastic breast reconstruction: should all patients be considered?; Neoadjuvant endocrine therapy: who benefits most?; Breast cancer disparities: how can we leverage genomics to improve outcomes?; Anatomy and breast cancer staging: is it still relevant?; When does atypical ductal hyperplasia require surgical intervention?; Surgical intervention for lymphedema; Are there alternative strategies in the local management of DCIS?; Genetic testing and genetic counseling: what is standard of care?; Molecular subtypes and local-regional control of breast cancer; Intraoperative margin assessment in breast cancer management; Triple negative breast cancer: who should receive neoadjuvant chemotherapy?; and more!

In this issue, guest editors bring their considerable expertise to this important topic. Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

It has been recognized for many years that cancers originating in the breast and prostate gland are frequently 'endocrine-dependent. ' Traditional thera pies included surgical endocrine ablative procedures or pharmacologic hor mone administration, both designed to antagonize the stimulatory effects of sex steroid hormones. In the past decade, several new treatment strategies for these tumors have emerged from basic studies in reproductive biology and mechanisms of action of steroid hormones. In some instances, these new treatments have elimin ated or reduced the need for major surgical ablative procedures or for toxic hormone therapy. The clinical role for other new treatments has not yet been clearly defined, although exciting preliminary data from recent clinical trials are now available. Thus, an objective review of the current status of these new therapeutic approaches is of interest. In this volume we have attempted to provide an in-depth review of both basic and clinical research involving several new treatment strategies for breast and prostate cancer. The first three chapters summarize preclinical and clinical studies of the luteinizing hormone-releasing hormone analogues, which can be used effectively to induce 'medical castration. ' Chapters 4, 5, and 6 review the rationale and clinical use of the compounds known collec tively as the aromatase inhibitors, which can also be used to suppress sex steroid hormone levels. Antiestrogen mechanism of action and its clinical implications for the design of innovative treatment approaches is considered in chapters 7 and 8.

The European School of Oncology came into existence to respond to a need for informa tion, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Univer sities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology.